The Xuri cell expansion systems (Xuri W25 and W5) provide a functionally closed, single-use bioreactor that requires fewer operator intervention steps, reduces the risk of contamination, and controls the cellular environment to maximize cell yield. Data presented here highlight that at a cellular level, results from different bioreactors may appear similar, but differences can exist at the receptor expression level.
Expansion of T Cells
Peripheral blood mononuclear cells (PBMCs) were expanded in static culture. On Day 5, 2-L Xuri Cellbag bioreactors were placed on the Xuri W5 system — at 37 °C, 5% CO2, a 10-rpm rock rate, and 6° rocking angle. Semicontinuous perfusion was initiated when the volume reached 1 L and cell density = 2 × 106 cells/mL.
For the 0.5-L stirred tank (STR) and 1-L gas-permeable static bioreactors, cells were incubated at 37 °C and 5% CO2 until the maximum working volume was achieved. Fresh medium was replenished every 48–72 hours, and cells from the waste medium were returned to the culture.
Cellular phenotype was analyzed at day 10 on a BD LSRFortessa™ flow cytometer. Briefly, 1 × 106 cells were labeled with CD3-perCP-Cy5.5, CD4-PE, CD8-Alexa Fluor488, CD28-APC and CD27-V450, or CD57-APC and CD62L-V450.
Enabling control of the cell culture environment during the expansion of T cells can provides a consistent culture environment with respect to cell health and phenotype. Xuri cell expansion systems offer an automated perfusion approach that can increase cell yield and viability as well as reduce the risks associated with operator intervention.
Ray Ismail (email@example.com) is a senior scientist, Sarah Stone is a stem cell laboratory technician, Bill Shingleton is an R&D team leader, Paul Bowles and Angela Marenghi are development scientists, and Mark Briggs is a senior program manager at GE Healthcare Life Sciences.
Disclaimer: The Xuri cell expansion systems W5 and W25 and Xuri Cellbag bioreactor are not medical devices nor CE marked and should not be used in diagnostic processes. Drug manufacturers and clinicians are responsible for obtaining the appropriate IND/BLA/NDA approvals for clinical applications. GE, Imagination at work, and GE Monogram are trademarks of General Electric Company. © 2014 General Electric Company — all rights reserved. First published October 2013. Xuri is trademark of GE Healthcare Companies. GlutaMax and Alexa fluor are trademarks of Life Technologies. X-VIVO 10 is a trademark of Lonza. LSRFortessa is a trademark of Becton, Dickinson and Company. Vi-CELL is a trademark of Beckman Coulter. Xuri Cell Expansion products are for research use only and not intended for diagnostic use. Drug manufacturers and clinicians are responsible for obtaining the appropriate IND/BLA/NDA approvals for clinical applications. GE Healthcare UK Limited. Amersham Place, Little Chalfont, Buckinghamshire, HP7 9NA UK.